BMS-181885, a 5-HT 1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential

Author： Saxena P.R.   De Vries P.   Heiligers J.P.C.   Bax W.A.   MaassenVanDenBrink A.   Yocca F.D.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.351, Iss.3, 1998-06, pp. : 329-339

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Investigations with GMC2021 in experimental models predictive of antimigraine activity and coronary side-effect potential

By Saxena P.R.   De Vries P.   Heiligers J.P.C.   VanDenBrink A.M.   Bax W.A.   Barf T.   Wikstrom H.  

European Journal of Pharmacology, Vol. 312, Iss. 1, 1996-09 ,pp. : 53-62

Elsevier

Access to resources Recommend Favorite

5-HT 1B/D Receptor Antagonists

By Pauwels P.J.  

General Pharmacology, Vol. 29, Iss. 3, 1997-09 ,pp. : 293-303

Elsevier

Access to resources Recommend Favorite

Recent Advances in 5-HT1B / 1D Receptor Antagonists and Agonists and their Potential Therapeutic Applications

By  

Current Topics in Medicinal Chemistry, Vol. 2, Iss. 6, 2002-06 ,pp. : 559-574

Bentham Science Publishers

Access to resources Recommend Favorite

The activity of 5-HT 1D receptor ligands at cloned human 5-HT 1D and 5-HT 1D receptors

By Walsh D.M.   Beattie D.T.   Connor H.E.  

European Journal of Pharmacology, Vol. 287, Iss. 1, 1995-12 ,pp. : 79-84

Elsevier

Access to resources Recommend Favorite

The antimigraine agent alniditan selectively constricts porcine carotid arteriovenous anastomoses via 5-HT 1B/1D receptors

By De Vries P.   Willems E.W.   Heiligers J.P.C.   Villalon C.M.   Saxena P.R.  

European Journal of Pharmacology, Vol. 351, Iss. 2, 1998-06 ,pp. : 193-201

Elsevier

Access to resources Recommend Favorite